Franklin Resources Inc Supernus Pharmaceuticals, Inc. Transaction History

Franklin Resources Inc

$378 Billion
Q3 2025

A detailed history of Franklin Resources Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Franklin Resources Inc holds 95,383 shares of SUPN stock, worth $4.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

95,383

Previous 39,855 139.33%

Holding current value

$4.29 Million

Previous $1.26 Million 262.9%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$31.45 - $47.79 $1.75 Million - $2.65 Million	55,528 Added 139.33%	95,383 $4.56 Million
Q2 2025 Aug 12, 2025	BUY	$30.29 - $33.43 $57,460 - $63,416	1,897 Added 5.0%	39,855 $1.26 Million
Q1 2025 May 13, 2025	BUY	$31.17 - $40.0 $197,929 - $254,000	6,350 Added 20.09%	37,958 $1.24 Million
Q4 2024 Feb 12, 2025	BUY	$31.89 - $37.83 $51,885 - $61,549	1,627 Added 5.43%	31,608 $1.14 Million
Q3 2024 Nov 12, 2024	BUY	$25.77 - $35.16 $54,658 - $74,574	2,121 Added 7.61%	29,981 $934,000

Q2 2024 Aug 14, 2024	BUY	$25.99 - $33.85 $83,609 - $108,895	3,217 Added 13.05%	27,860 $745,000
Q1 2024 May 13, 2024	SELL	$27.11 - $35.17 $29,089 - $37,737	-1,073 Reduced 4.17%	24,643 $840,000
Q4 2023 Feb 09, 2024	SELL	$22.72 - $29.68 $70,477 - $92,067	-3,102 Reduced 10.76%	25,716 $744,000
Q3 2023 Nov 13, 2023	SELL	$27.57 - $32.91 $10,669 - $12,736	-387 Reduced 1.33%	28,818 $794,000
Q2 2023 Aug 11, 2023	BUY	$29.91 - $38.73 $706,593 - $914,957	23,624 Added 423.29%	29,205 $877,000
Q1 2023 May 12, 2023	BUY	$34.93 - $42.03 $194,944 - $234,569	5,581 New	5,581 $202,000

Others Institutions Holding SUPN

# of Institutions

330

Shares Held

60.2M

Call Options Held

234K

Put Options Held

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.41B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

News

Stay updated on Franklin Resources Inc with notifications on news.

Account

Franklin Resources Inc Supernus Pharmaceuticals, Inc. Transaction History